Therefore, we searched for studies focusing on TNF-α antibodies and other biological agents that were prescribed to patients with ICI-induced myocarditis, aiming to provide more clinical information for the selection of biological agents, time of intervention, efficacy and safety. This evidence concerns the gene TNF and myocarditis.